H.C. Wainwright disclosed Summit Therapeutics (OTCMKTS:SMMT), hiking its stock price target to $26.00 earlier today
- Updated: September 16, 2016
In an issued report on 9/16/2016 H.C. Wainwright increased the target price of Summit Therapeutics (OTCMKTS:SMMT) from $0 to $26 indicating a possible upside of 3.73%.
Only yesterday Summit Therapeutics (OTCMKTS:SMMT) traded 12.00% lower at $5.50. The company’s 50-day average is $6.74 and its 200-day moving average is $7.48. The last stock price is down 26.49% relative to the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. Volume of trade was was up over the average, with 21,721 shares of SMMT changing hands over the typical 4,155 shares..
See Graph Below:
Summit Therapeutics has a 52 week low of $4.26 and a 52 week high of $12.78 . SMMT’s total market value is currently $0.0.
Also covering Summit Therapeutics’s target price, a total of 4 brokerages have released a research note on the company. The average target price is $22.00 with 0 rating the company a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 analystsrating the stock as sell.
About Summit Therapeutics (OTCMKTS:SMMT)
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease; and Ridinilazole, an orally administered small molecule antibiotic, which is in Phase II clinical trials for the treatment of Clostridium difficile infection disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, and the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.